A Phase 2/3, Multicenter, Open-Label Phase followed by a Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Infigratinib in Children with Hypochondroplasia: ACCEL 2/3
To determine if infigratinib, a new drug, is effective in increasing the growth of patients with a diagnosis of Hypochondroplasia
Why this Research Matters
Randomized Double-Blind Trial
Who can Participate
Child and Teen
Diagnosis of Hypochondroplsia, participation in ACCEL 0 trial
Study ID
Protocol Number: 25-0109
Meet the Team
Principal Investigator